APC-300 is a natural compound that, in pre-clinical studies, has been shown to not only inhibit the growth, but also to stimulate the death of human prostate cancer cells. APC-300 is a small molecule signal transduction inhibitor that acts as an anti-inflammatory agent and blocks prostate cancer progression in in vivo models of the disease. In addition to prostate cancer, APC-300 has also demonstrated efficacy in disease models of human melanoma and pancreatic cancer. Adamis believes that APC-300 may have potential applications in the treatment of several tumor types. APC-300 is currently in preclinical development. APC-300 has received $6.4 million in grant awards as a therapeutic oral drug for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.